Breaking News, Promotions & Moves

Regel Therapeutics Names New CEO

Dr. Stephen J. Farr previously served as President and CEO of Zogenix from 2015 until its acquisition by UCB in 2022.

Author Image

By: Charlie Sternberg

Associate Editor

Regel Therapeutics, a gene regulation company, has tapped Stephen J. Farr, PhD, as its Chief Executive Officer (CEO).   Farr served as President and CEO of Zogenix from 2015 until its acquisition by UCB in 2022. He transformed Zogenix into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, Europe and Japan. Before that, Farr served as Zogenix’s President and Chief Operating Officer since its founding in 2006. Previously, Farr was Sr. Vice President and Chi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters